RxDoctor Payments Data

Paige Helton

Family · Bloomfield, IANPI 1104532357

Payments from drug & device makers

$1,013in general payments, 2019–2025

Across 51 payments — averaging $19.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$110
  • Bayer$86
  • Pfizer$78
  • Lilly USA, LLC$77
  • Novartis$75
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$68
  • plus $519 from 13 others

What the payments were for

  • Food & beverage$1,013100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,013 in reported general payments places this provider in the 80th percentile of 1,268 family providers in Iowa.

See all family providers in Iowa

Medicare billing

Part B allowed, 2024
$152
Medicare patients
12
Services billed
13

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban99$44,127
OzempicSemaglutide41$38,126
LinzessLinaclotide132$34,212
JardianceEmpagliflozin27$24,551
MyrbetriqMirabegron76$18,601
TradjentaLinagliptin62$17,994
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$15,257
RybelsusSemaglutide12$11,306
TrulicityDulaglutide11$11,247
Tresiba Flextouch U-100Insulin Degludec20$11,109
VeozahFezolinetant11$7,761
Fiasp FlextouchInsulin Aspart (Niacinamide)13$7,722
EntrestoSacubitril/Valsartan11$6,861
XareltoRivaroxaban20$6,178
JanuviaSitagliptin Phosphate19$5,339

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$110$49,43153 claims
PfizerEliquis$78$44,12799 claims
Boehringer IngelheimJardiance, Tradjenta$44$42,54589 claims
AbbVieLinzess$59$34,212132 claims
Astellas Pharma US IncMyrbetriq, Veozah$18$26,36387 claims
Lilly USA, LLCTrulicity$77$11,24711 claims
NovartisEntresto$75$6,86111 claims
MerckJanuvia$54$5,33919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,268 family providers in Iowa.

Other family in Bloomfield

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →